Leveraging RWE to gain coverage and secure reimbursement

How life sciences leaders can accelerate market access success 

Real-world evidence (RWE) can help pharmaceutical and medical device companies in a variety of ways. From determining the effectiveness of a therapeutic to demonstrating the product’s economic value to helping gain coverage and acceptance from payers and providers, the opportunities are far-reaching. However, knowing when to tap into RWE and how to use it during the product development life cycle can help accelerate your therapeutic for market access success. 

Join Baker Tilly for an informative webinar discussing the importance of utilizing RWE. In addition to discussing what payers and providers are looking for in order to provide coverage and utilize your therapeutic, our team will also discuss how life sciences companies can gain a better understanding of knowing the right time and place to use RWE during the product life cycle to accelerate the adoption and success of your product or device. 

 Who should attend 

• CEOs, presidents, CFOs, CIOs, COOs, vice presidents, government affairs, health policy and other management professionals in life sciences organizations 

Presenters 

• David Gregory, MPA, FACHE, Principal, Baker Tilly 
• Grace Macalino, PhD, MPH, Director, Baker Tilly 

Learning objectives 

• Identify the various ways in which RWE can assist in determining the effectiveness of a product or device, demonstrating its economic value, and aiding in gaining coverage and acceptance from payers and providers 
• Recognize the criteria that payers and providers use to determine coverage and utilization of a therapeutic and understand how RWE can play a crucial role in meeting those standards 
• Understand how and when to utilize RWE during the product development life cycle to accelerate the adoption and success of your product or device